- Amended Statement of Ownership (SC 13G/A)
16 February 2010 - 10:06PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 3)*
IDENIX PHARMACEUTICALS, INC.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
45166R 20 4
(CUSIP Number)
December 31, 2009
(Date of Event Which Requires Filing of This Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
|
|
o
|
|
Rule 13d-1(b)
|
|
|
|
|
o
|
|
Rule 13d-1(c)
|
|
|
|
|
þ
|
|
Rule 13d-1(d)
|
*The remainder of this cover page shall be filled out for a reporting person’s initial filing on
this form with respect to the subject class of securities, and for any subsequent amendment
containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be “filed” for
the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to
the liabilities of that section of the Act but shall be subject to all other provisions of the Act
(however, see the Notes).
|
|
|
|
|
|
|
|
1
|
|
NAME OF REPORTING PERSONS
I.R.S. Identification No(s). of above person(s) (entities only)
BB BioVentures L.P.
|
|
|
|
|
|
|
|
|
|
2
|
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
|
|
|
(a)
o
|
|
|
(b)
þ
|
|
|
|
|
|
3
|
|
SEC USE ONLY
|
|
|
|
|
|
|
|
|
|
|
|
4
|
|
CITIZENSHIP OR PLACE OF ORGANIZATION
|
|
|
|
|
|
Delaware
|
|
|
|
|
|
|
|
5
|
|
SOLE VOTING POWER
|
|
|
|
|
|
NUMBER OF
|
|
2,949,488
|
|
|
|
|
|
|
SHARES
|
6
|
|
SHARED VOTING POWER
|
|
BENEFICIALLY
|
|
|
|
OWNED BY
|
|
0
|
|
|
|
|
|
|
EACH
|
7
|
|
SOLE DISPOSITIVE POWER
|
|
REPORTING
|
|
|
|
PERSON
|
|
2,949,488
|
|
|
|
|
|
|
WITH:
|
8
|
|
SHARED DISPOSITIVE POWER
|
|
|
|
|
|
|
|
0
|
|
|
|
|
|
9
|
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
|
|
|
|
|
2,949,488
|
|
|
|
|
|
10
|
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
|
|
|
|
|
|
o
|
|
|
|
|
|
11
|
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
|
|
|
|
|
|
4.5%
|
|
|
|
|
|
12
|
|
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
|
|
|
|
|
|
PN
|
Page 2 of 20
|
|
|
|
|
|
|
|
1
|
|
NAME OF REPORTING PERSONS
I.R.S. Identification No(s). of above person(s) (entities only)
MPM BioVentures Parallel Fund, L.P.
|
|
|
|
|
|
|
|
|
|
2
|
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
|
|
|
(a)
o
|
|
|
(b)
þ
|
|
|
|
|
|
3
|
|
SEC USE ONLY
|
|
|
|
|
|
|
|
|
|
|
|
4
|
|
CITIZENSHIP OR PLACE OF ORGANIZATION
|
|
|
|
|
|
Delaware
|
|
|
|
|
|
|
|
5
|
|
SOLE VOTING POWER
|
|
|
|
|
|
NUMBER OF
|
|
256,519
|
|
|
|
|
|
|
SHARES
|
6
|
|
SHARED VOTING POWER
|
|
BENEFICIALLY
|
|
|
|
OWNED BY
|
|
0
|
|
|
|
|
|
|
EACH
|
7
|
|
SOLE DISPOSITIVE POWER
|
|
REPORTING
|
|
|
|
PERSON
|
|
256,519
|
|
|
|
|
|
|
WITH:
|
8
|
|
SHARED DISPOSITIVE POWER
|
|
|
|
|
|
|
|
0
|
|
|
|
|
|
9
|
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
|
|
|
|
|
256,519
|
|
|
|
|
|
10
|
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
|
|
|
|
|
|
o
|
|
|
|
|
|
11
|
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
|
|
|
|
|
|
0.4%
|
|
|
|
|
|
12
|
|
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
|
|
|
|
|
|
PN
|
Page 3 of 20
|
|
|
|
|
|
|
|
1
|
|
NAME OF REPORTING PERSONS
I.R.S. Identification No(s). of above person(s) (entities only)
MPM Asset Management Investors 1998 LLC
|
|
|
|
|
|
|
|
|
|
2
|
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
|
|
|
(a)
o
|
|
|
(b)
þ
|
|
|
|
|
|
3
|
|
SEC USE ONLY
|
|
|
|
|
|
|
|
|
|
|
|
4
|
|
CITIZENSHIP OR PLACE OF ORGANIZATION
|
|
|
|
|
|
Delaware
|
|
|
|
|
|
|
|
5
|
|
SOLE VOTING POWER
|
|
|
|
|
|
NUMBER OF
|
|
37,299
|
|
|
|
|
|
|
SHARES
|
6
|
|
SHARED VOTING POWER
|
|
BENEFICIALLY
|
|
|
|
OWNED BY
|
|
0
|
|
|
|
|
|
|
EACH
|
7
|
|
SOLE DISPOSITIVE POWER
|
|
REPORTING
|
|
|
|
PERSON
|
|
37,299
|
|
|
|
|
|
|
WITH:
|
8
|
|
SHARED DISPOSITIVE POWER
|
|
|
|
|
|
|
|
0
|
|
|
|
|
|
9
|
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
|
|
|
|
|
37,299
|
|
|
|
|
|
10
|
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
|
|
|
|
|
|
o
|
|
|
|
|
|
11
|
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
|
|
|
|
|
|
0.1%
|
|
|
|
|
|
12
|
|
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
|
|
|
|
|
|
OO
|
Page 4 of 20
|
|
|
|
|
|
|
|
1
|
|
NAME OF REPORTING PERSONS
I.R.S. Identification No(s). of above person(s) (entities only)
MPM Asset Management LLC
|
|
|
|
|
|
|
|
|
|
2
|
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
|
|
|
(a)
o
|
|
|
(b)
þ
|
|
|
|
|
|
3
|
|
SEC USE ONLY
|
|
|
|
|
|
|
|
|
|
|
|
4
|
|
CITIZENSHIP OR PLACE OF ORGANIZATION
|
|
|
|
|
|
Delaware
|
|
|
|
|
|
|
|
5
|
|
SOLE VOTING POWER
|
|
|
|
|
|
NUMBER OF
|
|
78,228
|
|
|
|
|
|
|
SHARES
|
6
|
|
SHARED VOTING POWER
|
|
BENEFICIALLY
|
|
|
|
OWNED BY
|
|
0
|
|
|
|
|
|
|
EACH
|
7
|
|
SOLE DISPOSITIVE POWER
|
|
REPORTING
|
|
|
|
PERSON
|
|
78,228
|
|
|
|
|
|
|
WITH:
|
8
|
|
SHARED DISPOSITIVE POWER
|
|
|
|
|
|
|
|
0
|
|
|
|
|
|
9
|
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
|
|
|
|
|
78,228
|
|
|
|
|
|
10
|
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
|
|
|
|
|
|
o
|
|
|
|
|
|
11
|
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
|
|
|
|
|
|
0.1%
|
|
|
|
|
|
12
|
|
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
|
|
|
|
|
|
OO
|
Page 5 of 20
|
|
|
|
|
|
|
|
1
|
|
NAME OF REPORTING PERSONS
I.R.S. Identification No(s). of above person(s) (entities only)
MPM BioVentures I, L.P.
|
|
|
|
|
|
|
|
|
|
2
|
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
|
|
|
(a)
o
|
|
|
(b)
þ
|
|
|
|
|
|
3
|
|
SEC USE ONLY
|
|
|
|
|
|
|
|
|
|
|
|
4
|
|
CITIZENSHIP OR PLACE OF ORGANIZATION
|
|
|
|
|
|
Delaware
|
|
|
|
|
|
|
|
5
|
|
SOLE VOTING POWER
|
|
|
|
|
|
NUMBER OF
|
|
256,519*
|
|
|
|
|
|
|
SHARES
|
6
|
|
SHARED VOTING POWER
|
|
BENEFICIALLY
|
|
|
|
OWNED BY
|
|
0
|
|
|
|
|
|
|
EACH
|
7
|
|
SOLE DISPOSITIVE POWER
|
|
REPORTING
|
|
|
|
PERSON
|
|
256,519*
|
|
|
|
|
|
|
WITH:
|
8
|
|
SHARED DISPOSITIVE POWER
|
|
|
|
|
|
|
|
0
|
|
|
|
|
|
9
|
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
|
|
|
|
|
256,519*
|
|
|
|
|
|
10
|
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
|
|
|
|
|
|
o
|
|
|
|
|
|
11
|
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
|
|
|
|
|
|
0.4%
|
|
|
|
|
|
12
|
|
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
|
|
|
|
|
|
PN
|
* The shares are held
by MPM BioVentures Parallel Fund, L.P., of which the Reporting
Person is its general partner.
Page 6 of 20
|
|
|
|
|
|
|
|
1
|
|
NAME OF REPORTING PERSONS
I.R.S. Identification No(s). of above person(s) (entities only)
MPM BioVentures I LLC
|
|
|
|
|
|
|
|
|
|
2
|
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
|
|
|
(a)
o
|
|
|
(b)
þ
|
|
|
|
|
|
3
|
|
SEC USE ONLY
|
|
|
|
|
|
|
|
|
|
|
|
4
|
|
CITIZENSHIP OR PLACE OF ORGANIZATION
|
|
|
|
|
|
Delaware
|
|
|
|
|
|
|
|
5
|
|
SOLE VOTING POWER
|
|
|
|
|
|
NUMBER OF
|
|
3,206,007*
|
|
|
|
|
|
|
SHARES
|
6
|
|
SHARED VOTING POWER
|
|
BENEFICIALLY
|
|
|
|
OWNED BY
|
|
0
|
|
|
|
|
|
|
EACH
|
7
|
|
SOLE DISPOSITIVE POWER
|
|
REPORTING
|
|
|
|
PERSON
|
|
3,206,007*
|
|
|
|
|
|
|
WITH:
|
8
|
|
SHARED DISPOSITIVE POWER
|
|
|
|
|
|
|
|
0
|
|
|
|
|
|
9
|
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
|
|
|
|
|
3,206,007*
|
|
|
|
|
|
10
|
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
|
|
|
|
|
|
o
|
|
|
|
|
|
11
|
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
|
|
|
|
|
|
4.8%
|
|
|
|
|
|
12
|
|
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
|
|
|
|
|
|
OO
|
** The shares are held as follows: 256,519 by MPM BioVentures Parallel Fund, L.P. (“MPM Parallel”) and 2,949,488 by BB BioVentures, L.P. (“BB BioVentures”). The Reporting Person is the indirect general partner of MPM Parallel and BB BioVentures.
Page 7 of 20
|
|
|
|
|
|
|
|
1
|
|
NAME OF REPORTING PERSONS
I.R.S. Identification No(s). of above person(s) (entities only)
BAB BioVentures L.P.
|
|
|
|
|
|
|
|
|
|
2
|
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
|
|
|
(a)
o
|
|
|
(b)
þ
|
|
|
|
|
|
3
|
|
SEC USE ONLY
|
|
|
|
|
|
|
|
|
|
|
|
4
|
|
CITIZENSHIP OR PLACE OF ORGANIZATION
|
|
|
|
|
|
Delaware
|
|
|
|
|
|
|
|
5
|
|
SOLE VOTING POWER
|
|
|
|
|
|
NUMBER OF
|
|
2,949,488*
|
|
|
|
|
|
|
SHARES
|
6
|
|
SHARED VOTING POWER
|
|
BENEFICIALLY
|
|
|
|
OWNED BY
|
|
0
|
|
|
|
|
|
|
EACH
|
7
|
|
SOLE DISPOSITIVE POWER
|
|
REPORTING
|
|
|
|
PERSON
|
|
2,949,488*
|
|
|
|
|
|
|
WITH:
|
8
|
|
SHARED DISPOSITIVE POWER
|
|
|
|
|
|
|
|
0
|
|
|
|
|
|
9
|
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
|
|
|
|
|
2,949,488*
|
|
|
|
|
|
10
|
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
|
|
|
|
|
|
o
|
|
|
|
|
|
11
|
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
|
|
|
|
|
|
4.5%
|
|
|
|
|
|
12
|
|
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
|
|
|
|
|
|
PN
|
** The shares are by BB BioVentures, L.P., of which the Reporting Person is the direct general partner.
Page 8 of 20
|
|
|
|
|
|
|
|
1
|
|
NAME OF REPORTING PERSONS
I.R.S. Identification No(s). of above person(s) (entities only)
BAB BioVentures, N.V.
|
|
|
|
|
|
|
|
|
|
2
|
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
|
|
|
(a)
o
|
|
|
(b)
þ
|
|
|
|
|
|
3
|
|
SEC USE ONLY
|
|
|
|
|
|
|
|
|
|
|
|
4
|
|
CITIZENSHIP OR PLACE OF ORGANIZATION
|
|
|
|
|
|
Netherlands Antilles
|
|
|
|
|
|
|
|
5
|
|
SOLE VOTING POWER
|
|
|
|
|
|
NUMBER OF
|
|
2,949,488*
|
|
|
|
|
|
|
SHARES
|
6
|
|
SHARED VOTING POWER
|
|
BENEFICIALLY
|
|
|
|
OWNED BY
|
|
0
|
|
|
|
|
|
|
EACH
|
7
|
|
SOLE DISPOSITIVE POWER
|
|
REPORTING
|
|
|
|
PERSON
|
|
2,949,488*
|
|
|
|
|
|
|
WITH:
|
8
|
|
SHARED DISPOSITIVE POWER
|
|
|
|
|
|
|
|
0
|
|
|
|
|
|
9
|
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
|
|
|
|
|
2,949,488*
|
|
|
|
|
|
10
|
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
|
|
|
|
|
|
o
|
|
|
|
|
|
11
|
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
|
|
|
|
|
|
4.5%
|
|
|
|
|
|
12
|
|
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
|
|
|
|
|
|
PN
|
** The shares are by BB BioVentures, L.P., of which the Reporting Person is the indirect general partner.
Page 9 of 20
|
|
|
|
|
|
|
|
1
|
|
NAME OF REPORTING PERSONS
I.R.S. Identification No(s). of above person(s) (entities only)
Ansbert Gadicke
|
|
|
|
|
|
|
|
|
|
2
|
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
|
|
|
(a)
o
|
|
|
(b)
þ
|
|
|
|
|
|
3
|
|
SEC USE ONLY
|
|
|
|
|
|
|
|
|
|
|
|
4
|
|
CITIZENSHIP OR PLACE OF ORGANIZATION
|
|
|
|
|
|
United States
|
|
|
|
|
|
|
|
5
|
|
SOLE VOTING POWER
|
|
|
|
|
|
NUMBER OF
|
|
0
|
|
|
|
|
|
|
SHARES
|
6
|
|
SHARED VOTING POWER
|
|
BENEFICIALLY
|
|
|
|
OWNED BY
|
|
3,321,534*
|
|
|
|
|
|
|
EACH
|
7
|
|
SOLE DISPOSITIVE POWER
|
|
REPORTING
|
|
|
|
PERSON
|
|
0
|
|
|
|
|
|
|
WITH:
|
8
|
|
SHARED DISPOSITIVE POWER
|
|
|
|
|
|
|
|
3,321,534*
|
|
|
|
|
|
9
|
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
|
|
|
|
|
3,321,534*
|
|
|
|
|
|
10
|
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
|
|
|
|
|
|
o
|
|
|
|
|
|
11
|
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
|
|
|
|
|
|
5.0%
|
|
|
|
|
|
12
|
|
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
|
|
|
|
|
|
IN
|
*The shares are held as follows: 2,949,488 by BB BioVentures L.P. (“BB BioVentures”), 256,519 by MPM BioVentures
Parallel Fund, L.P. (“MPM Parallel”), 37,299 by MPM Asset Management Investors 1998 LLC (“MPM Investors”) and 78,228 by MPM Asset Management LLC
(“AM LLC”).
MPM BioVentures I, L.P. and MPM BioVentures I LLC (“BioVentures LLC”) are the direct and indirect general partners of MPM Parallel. BAB BioVentures
L.P. (“BAB BV”), BAB BioVentures NV and BioVentures LLC are the direct and indirect general partners of BB BioVentures. The Reporting Person is
a manager of MPM Investors, AM LLC and BioVentures LLC.
Page 10 of 20
|
|
|
|
|
|
|
|
1
|
|
NAME OF REPORTING PERSONS
I.R.S. Identification No(s). of above person(s) (entities only)
Luke Evnin
|
|
|
|
|
|
|
|
|
|
2
|
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
|
|
|
(a)
o
|
|
|
(b)
þ
|
|
|
|
|
|
3
|
|
SEC USE ONLY
|
|
|
|
|
|
|
|
|
|
|
|
4
|
|
CITIZENSHIP OR PLACE OF ORGANIZATION
|
|
|
|
|
|
United States
|
|
|
|
|
|
|
|
5
|
|
SOLE VOTING POWER
|
|
|
|
|
|
NUMBER OF
|
|
0
|
|
|
|
|
|
|
SHARES
|
6
|
|
SHARED VOTING POWER
|
|
BENEFICIALLY
|
|
|
|
OWNED BY
|
|
3,321,534*
|
|
|
|
|
|
|
EACH
|
7
|
|
SOLE DISPOSITIVE POWER
|
|
REPORTING
|
|
|
|
PERSON
|
|
0
|
|
|
|
|
|
|
WITH:
|
8
|
|
SHARED DISPOSITIVE POWER
|
|
|
|
|
|
|
|
3,321,534*
|
|
|
|
|
|
9
|
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
|
|
|
|
|
3,321,534*
|
|
|
|
|
|
10
|
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
|
|
|
|
|
|
o
|
|
|
|
|
|
11
|
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
|
|
|
|
|
|
5.0%
|
|
|
|
|
|
12
|
|
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
|
|
|
|
|
|
IN
|
*The shares are held as follows: 2,949,488 by BB BioVentures, 256,519 by MPM Parallel, 37,299 by MPM Investors and 78,228 by AM LLC. MPM BioVentures I, L.P. and BioVentures LLC are the direct and indirect general partners of MPM Parallel. BAB BV, BAB BioVentures NV and BioVentures LLC are the direct and indirect general partners of BB BioVentures. The Reporting Person is a manager of MPM Investors, AM LLC and BioVentures LLC.
Page 11 of 20
|
|
|
|
|
|
|
|
1
|
|
NAME OF REPORTING PERSONS
I.R.S. Identification No(s). of above person(s) (entities only)
Michael Steinmetz
|
|
|
|
|
|
|
|
|
|
2
|
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
|
|
|
(a)
o
|
|
|
(b)
þ
|
|
|
|
|
|
3
|
|
SEC USE ONLY
|
|
|
|
|
|
|
|
|
|
|
|
4
|
|
CITIZENSHIP OR PLACE OF ORGANIZATION
|
|
|
|
|
|
United States
|
|
|
|
|
|
|
|
5
|
|
SOLE VOTING POWER
|
|
|
|
|
|
NUMBER OF
|
|
0
|
|
|
|
|
|
|
SHARES
|
6
|
|
SHARED VOTING POWER
|
|
BENEFICIALLY
|
|
|
|
OWNED BY
|
|
3,243,306*
|
|
|
|
|
|
|
EACH
|
7
|
|
SOLE DISPOSITIVE POWER
|
|
REPORTING
|
|
|
|
PERSON
|
|
0
|
|
|
|
|
|
|
WITH:
|
8
|
|
SHARED DISPOSITIVE POWER
|
|
|
|
|
|
|
|
3,243,306*
|
|
|
|
|
|
9
|
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
|
|
|
|
|
3,243,306*
|
|
|
|
|
|
10
|
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
|
|
|
|
|
|
o
|
|
|
|
|
|
11
|
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
|
|
|
|
|
|
4.9%
|
|
|
|
|
|
12
|
|
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
|
|
|
|
|
|
IN
|
*The shares are held as follows: 2,949,488 by BB BioVentures, 256,519 by MPM Parallel and 37,299 by MPM Investors. MPM BioVentures I, L.P. and BioVentures LLC are the direct and indirect general partners of MPM Parallel. BAB BV, BAB BioVentures NV and BioVentures LLC are the direct and indirect general partners of BB BioVentures. The Reporting Person is a manager of MPM Investors and BioVentures LLC.
Page 12 of 20
Item 1.
|
|
(a)
|
|
Name of Issuer
|
|
|
|
|
|
|
Idenix Pharmaceuticals, Inc.
|
|
|
(b)
|
|
Address of Issuer’s Principal Executive Offices
|
|
|
|
|
|
|
60 Hampshire Street
|
|
|
|
|
Cambridge, MA 02139
|
Item 2.
|
|
(a)
|
|
Name of Person Filing
|
BB BioVentures, L.P.
MPM BioVentures Parallel Fund, L.P.
MPM Asset Management Investors 1998 LLC
MPM Asset Management LLC
MPM BioVentures I, L.P.
MPM BioVentures I LLC
BAB BioVentures L.P.
BAB BioVentures, N.V.
Ansbert Gadicke
Luke Evnin
Michael Steinmetz
|
|
(b)
|
|
Address of Principal Business Office or, if none, Residence
|
c/o MPM Capital L.P.
The John Hancock Tower
200 Clarendon Street, 54
th
Floor
Boston, MA 02116
All entities were organized in Delaware, except BAB BioVentures, N.V which
is organized in the Netherlands Antilles, and all individuals are United States
citizens.
|
|
(d)
|
|
Title of Class of Securities
|
Common Stock
45166R 20 4
|
|
|
|
|
Item 3.
|
|
If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c),
check whether the person filing is a:
|
Not applicable
Page 13 of 20
|
|
(a)
|
|
Amount Beneficially Owned:
|
|
|
|
|
|
|
|
BB BioVentures, LP
|
|
|
2,949,488
|
|
|
MPM BioVentures Parallel Fund, LP
|
|
|
256,519
|
|
|
MPM Asset Management Investors 1998 LLC
|
|
|
37,299
|
|
|
MPM Asset Management LLC
|
|
|
78,228
|
|
|
MPM BioVentures I, L.P.
|
|
|
256,519
|
(1)
|
|
MPM BioVentures I LLC
|
|
|
3,206,007
|
(2)
|
|
BAB BioVentures L.P.
|
|
|
2,949,488
|
(3)
|
|
BAB BioVentures, N.V.
|
|
|
2,949,488
|
(4)
|
|
Ansbert Gadicke
|
|
|
3,321,534
|
(5)
|
|
Luke Evnin
|
|
|
3,321,534
|
(5)
|
|
Michael Steinmetz
|
|
|
3,243,306
|
(6)
|
|
|
|
|
|
|
|
BB BioVentures, LP
|
|
|
4.5
|
%
|
|
MPM BioVentures Parallel Fund, LP
|
|
|
0.4
|
%
|
|
MPM Asset Management Investors 1998 LLC
|
|
|
0.1
|
%
|
|
MPM Asset Management LLC
|
|
|
0.1
|
%
|
|
MPM BioVentures I, L.P.
|
|
|
0.4
|
%
|
|
MPM BioVentures I LLC
|
|
|
4.8
|
%
|
|
BAB BioVentures L.P.
|
|
|
4.5
|
%
|
|
BAB BioVentures, N.V.
|
|
|
4.5
|
%
|
|
Ansbert Gadicke
|
|
|
5.0
|
%
|
|
Luke Evnin
|
|
|
5.0
|
%
|
|
Michael Steinmetz
|
|
|
4.9
|
%
|
|
|
(c)
|
|
Number of shares as to which the person has:
|
|
|
(i)
|
|
Sole power to vote or to direct the vote
|
|
|
|
|
|
|
|
BB BioVentures, LP
|
|
|
2,949,488
|
|
|
MPM BioVentures Parallel Fund, LP
|
|
|
256,519
|
|
|
MPM Asset Management Investors 1998 LLC
|
|
|
37,299
|
|
|
MPM Asset Management LLC
|
|
|
78,228
|
|
|
MPM BioVentures I, L.P.
|
|
|
0
|
|
Page 14 of 20
|
|
|
|
|
|
|
MPM BioVentures I LLC
|
|
|
0
|
|
|
BAB BioVentures L.P.
|
|
|
0
|
|
|
BAB BioVentures, N.V.
|
|
|
0
|
|
|
Ansbert Gadicke
|
|
|
0
|
|
|
Luke Evnin
|
|
|
0
|
|
|
Michael Steinmetz
|
|
|
0
|
|
|
|
(ii)
|
|
Shared power to vote or to direct the vote
|
|
|
|
|
|
|
|
BB BioVentures, LP
|
|
|
0
|
|
|
MPM BioVentures Parallel Fund, LP
|
|
|
0
|
|
|
MPM Asset Management Investors 1998 LLC
|
|
|
0
|
|
|
MPM Asset Management LLC
|
|
|
0
|
|
|
MPM BioVentures I, L.P.
|
|
|
256,519
|
(1)
|
|
MPM BioVentures I LLC
|
|
|
3,206,007
|
(2)
|
|
BAB BioVentures L.P.
|
|
|
2,949,488
|
(3)
|
|
BAB BioVentures, N.V.
|
|
|
2,949,488
|
(4)
|
|
Ansbert Gadicke
|
|
|
3,321,534
|
(5)
|
|
Luke Evnin
|
|
|
3,321,534
|
(5)
|
|
Michael Steinmetz
|
|
|
3,243,306
|
(6)
|
|
|
(iii)
|
|
Sole power to dispose or to direct the disposition of
|
|
|
|
|
|
|
|
BB BioVentures, LP
|
|
|
2,949,488
|
|
|
MPM BioVentures Parallel Fund, LP
|
|
|
256,519
|
|
|
MPM Asset Management Investors 1998 LLC
|
|
|
37,299
|
|
|
MPM Asset Management LLC
|
|
|
78,228
|
|
|
MPM BioVentures I, L.P.
|
|
|
0
|
|
|
MPM BioVentures I LLC
|
|
|
0
|
|
|
BAB BioVentures L.P.
|
|
|
0
|
|
|
BAB BioVentures, N.V.
|
|
|
0
|
|
|
Ansbert Gadicke
|
|
|
0
|
|
|
Luke Evnin
|
|
|
0
|
|
|
Michael Steinmetz
|
|
|
0
|
|
|
|
(iv)
|
|
Shared power to dispose or to direct the disposition of
|
|
|
|
|
|
|
|
BB BioVentures, LP
|
|
|
0
|
|
|
MPM BioVentures Parallel Fund, LP
|
|
|
0
|
|
|
MPM Asset Management Investors 1998 LLC
|
|
|
0
|
|
|
MPM Asset Management LLC
|
|
|
0
|
|
Page 15 of 20
|
|
|
|
|
|
|
MPM BioVentures I, L.P.
|
|
|
256,519
|
(1)
|
|
MPM BioVentures I LLC
|
|
|
3,206,007
|
(2)
|
|
BAB BioVentures L.P.
|
|
|
2,949,488
|
(3)
|
|
BAB BioVentures, N.V.
|
|
|
2,949,488
|
(4)
|
|
Ansbert Gadicke
|
|
|
3,321,534
|
(5)
|
|
Luke Evnin
|
|
|
3,321,534
|
(5)
|
|
Michael Steinmetz
|
|
|
3,243,306
|
(6)
|
|
|
|
|
|
(1)
|
|
The shares are held by MPM BioVentures Parallel Fund, L.P. (“MPM Parallel”), of which the
Reporting Person is its general partner.
|
|
|
|
(2)
|
|
The shares are held as follows: 256,519 by MPM Parallel and 2,949,488 by BB BioVentures, L.P.
(“BB BioVentures”). The Reporting Person is the indirect general partner of MPM Parallel and BB
BioVentures.
|
|
|
|
(3)
|
|
The shares are held by BB BioVentures, of which the Reporting Person is the direct general
partner.
|
|
|
|
(4)
|
|
The shares are held by BB BioVentures, of which the Reporting Person is the indirect general
partner.
|
|
|
|
(5)
|
|
The shares are held as follows: 2,949,488 by BB BioVentures, 256,519 by MPM Parallel, 37,299 by
MPM Asset Management Investors 1998 LLC (“MPM Investors”) and 78,228 by MPM Asset Management LLC
(“AM LLC”). MPM BioVentures I, L.P. and MPM BioVentures I LLC (“BioVentures LLC”) are the direct
and indirect general partners of MPM Parallel. BAB BioVentures L.P. (“BAB BV”), BAB BioVentures NV
and BioVentures LLC are the direct and indirect general partners of BB BioVentures. The Reporting
Person is a manager of MPM Investors, AM LLC and BioVentures LLC.
|
|
|
|
(6)
|
|
The shares are held as follows: 2,949,488 by BB BioVentures, 256,519 by MPM Parallel and 37,299
by MPM Investors. MPM BioVentures I, L.P. and BioVentures LLC are the direct and indirect general
partners of MPM Parallel. BAB BV, BAB BioVentures NV and BioVentures LLC are the direct and
indirect general partners of BB BioVentures. The Reporting Person is a manager of MPM Investors
and BioVentures LLC.
|
|
|
|
|
|
Item 5.
|
|
Ownership of Five Percent or Less of a Class
|
If this statement is being filed to report the fact that as of the date hereof the reporting person
has ceased to be the beneficial owner of more than five percent of the class of securities, check
the following
þ
.
|
|
|
|
|
Item 6.
|
|
Ownership of More than Five Percent on Behalf of Another Person
|
Not Applicable
|
|
|
|
|
Item 7.
|
|
Identification and Classification of the Subsidiary Which Acquired the Security
Being Reported on By the Parent Holding Company or Control Person.
|
Not Applicable
|
|
|
|
|
Item 8.
|
|
Identification and Classification of Members of the Group
|
Not Applicable
|
|
|
|
|
Item 9.
|
|
Notice of Dissolution of a Group
|
Not Applicable
Not Applicable
Page 16 of 20
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the
information set forth in this statement is true, complete and correct.
Dated:
February 11, 2010
|
|
|
|
|
|
|
|
|
|
|
|
|
BB BIOVENTURES L.P.
|
|
|
|
MPM BIOVENTURES PARALLEL FUND, L.P.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
BAB BioVentures L.P.,
|
|
|
|
By:
|
|
MPM BioVentures I LP,
|
|
|
|
|
|
its General Partner
|
|
|
|
|
|
its General Partner
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
BAB BioVentures N.V.,
|
|
|
|
By:
|
|
MPM BioVentures I LLC,
|
|
|
|
|
|
its General Partner
|
|
|
|
|
|
its General Partner
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Luke B. Evnin
Name: Luke B. Evnin
|
|
|
|
By:
|
|
/s/ Luke B. Evnin
Name: Luke B. Evnin
|
|
|
|
|
|
Title: Manager
|
|
|
|
|
|
Title: Manager
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
MPM ASSET MANAGEMENT INVESTORS 1998 LLC
|
|
|
|
MPM ASSET MANAGEMENT LLC
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Luke B. Evnin
Name: Luke B. Evnin
|
|
|
|
By:
|
|
/s/ Luke B. Evnin
Name: Luke B. Evnin
|
|
|
|
|
|
Title: Manager
|
|
|
|
|
|
Title: Manager
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
MPM BIOVENTURES I, L.P.
|
|
|
|
MPM BIOVENTURES I LLC
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
MPM BioVentures I LLC,
|
|
|
|
|
|
|
|
|
|
|
|
its General Partner
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Luke B. Evnin
Name: Luke B. Evnin
|
|
|
|
By:
|
|
/s/ Luke B. Evnin
Name: Luke B. Evnin
|
|
|
|
|
|
Title: Manager
|
|
|
|
|
|
Title: Manager
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BAB BIOVENTURES, L.P.
|
|
|
|
BAB BIOVENTURES, N.V.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
BAB BioVentures, N.V.
|
|
|
|
|
|
|
|
|
|
|
|
its General Partner
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Luke B. Evnin
Name: Luke B. Evnin
|
|
|
|
By:
|
|
/s/ Luke B. Evnin
Name: Luke B. Evnin
|
|
|
|
|
|
Title: Manager
|
|
|
|
|
|
Title: Manager
|
|
|
Page 17 of 20
|
|
|
|
/s/ Ansbert Gadicke
Ansbert Gadicke
|
|
|
|
|
|
|
/s/ Luke B. Evnin
Luke B. Evnin
|
|
|
|
|
|
|
/s/ Michael Steinmetz
Michael Steinmetz
|
|
|
Page 18 of 20
EXHIBIT A
JOINT FILING AGREEMENT
In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the
undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G
(including amendments thereto) with respect to the Common Stock of Idenix Pharmaceuticals, Inc. and
further agree that this agreement be included as an exhibit to such filing. Each party to the
agreement expressly authorizes each other party to file on its behalf any and all amendments to
such statement. Each party to this agreement agrees that this joint filing agreement may be signed
in counterparts.
In evidence whereof, the undersigned have caused this Agreement to be executed on their behalf
this 11
th
day of February, 2010.
|
|
|
|
|
|
|
|
|
|
|
|
|
BB BIOVENTURES L.P.
|
|
|
|
MPM BIOVENTURES PARALLEL FUND, L.P.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
BAB BioVentures L.P.,
|
|
|
|
By:
|
|
MPM BioVentures I LP,
|
|
|
|
|
|
its General Partner
|
|
|
|
|
|
its General Partner
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
BAB BioVentures N.V.,
|
|
|
|
By:
|
|
MPM BioVentures I LLC,
|
|
|
|
|
|
its General Partner
|
|
|
|
|
|
its General Partner
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Luke B. Evnin
Name: Luke B. Evnin
|
|
|
|
By:
|
|
/s/ Luke B. Evnin
Name: Luke B. Evnin
|
|
|
|
|
|
Title: Manager
|
|
|
|
|
|
Title: Manager
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
MPM ASSET MANAGEMENT INVESTORS 1998 LLC
|
|
|
|
MPM ASSET MANAGEMENT LLC
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Luke B. Evnin
Name: Luke B. Evnin
|
|
|
|
By:
|
|
/s/ Luke B. Evnin
Name: Luke B. Evnin
|
|
|
|
|
|
Title: Manager
|
|
|
|
|
|
Title: Manager
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
MPM BIOVENTURES I, L.P.
|
|
|
|
MPM BIOVENTURES I LLC
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
MPM BioVentures I LLC,
|
|
|
|
|
|
|
|
|
|
|
|
its General Partner
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Luke B. Evnin
Name: Luke B. Evnin
|
|
|
|
By:
|
|
/s/ Luke B. Evnin
Name: Luke B. Evnin
|
|
|
|
|
|
Title: Manager
|
|
|
|
|
|
Title: Manager
|
|
|
Page 19 of 20
|
|
|
|
|
|
|
|
|
|
|
|
|
BAB BIOVENTURES, L.P.
|
|
|
|
BAB BIOVENTURES, N.V.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
By: BAB BioVentures, N.V.
its General Partner
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Luke B. Evnin
Name: Luke B. Evnin
|
|
|
|
By:
|
|
/s/ Luke B. Evnin
Name: Luke B. Evnin
|
|
|
|
|
|
Title: Manager
|
|
|
|
|
|
Title: Manager
|
|
|
|
|
|
|
/s/ Ansbert Gadicke
Ansbert Gadicke
|
|
|
|
|
|
|
/s/ Luke B. Evnin
Luke B. Evnin
|
|
|
|
|
|
|
/s/ Michael Steinmetz
Michael Steinmetz
|
|
|
Page 20 of 20
(MM) (NASDAQ:IDIX)
Historical Stock Chart
From Jun 2024 to Jul 2024
(MM) (NASDAQ:IDIX)
Historical Stock Chart
From Jul 2023 to Jul 2024
